{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:29:01Z","timestamp":1781605741560,"version":"3.54.5"},"reference-count":36,"publisher":"BMJ","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA023074"],"award-info":[{"award-number":["P30 CA023074"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2016,10,30]]},"abstract":"<jats:p>Chemotherapy-induced cardiomyopathy is one of the major possible hazards that can result from potential cardiotoxic agents while treating cancer. Prognostic risk factors include the rate of drug administration, history of hypertension, female gender, extremes of age, previous history of mediastinal irradiation, cumulative dose and pre-existing heart disease. Close monitoring of the patients, timely diagnosis, use of well-known biomarkers including cardiac troponins, NT-ProBNP and imaging studies like 2D Echo or cardiac MRI are essential. Emerging biomarkers include carbonyl reductases (CBR1 and CBR3), aldo-keto reductases (AKR, type 1A1, 1C3, 7A2) and topoisomerase2\u03b2 (Top2\u03b2). \u03b2 blockers and ACE inhibitors have not only been shown to slow down the progression of cardiac dysfunction but also produce symptomatic improvement. Our case report describes a patient with acute myeloblastic leukaemia who developed severe cardiomyopathy acutely after starting the anthracycline-based regimen. Nevertheless, with timely intervention her symptoms improved and subsequently she successfully received allogeneic stem cell transplantation.<\/jats:p>","DOI":"10.1136\/bcr-2016-217210","type":"journal-article","created":{"date-parts":[[2016,11,16]],"date-time":"2016-11-16T21:29:21Z","timestamp":1479331761000},"page":"bcr2016217210","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Successful recovery and allogeneic stem cell transplant following chemotherapy-induced severe cardiomyopathy: literature review of management and prognostic factors"],"prefix":"10.1136","volume":"2016","author":[{"given":"Muhammad Asim","family":"Shahzad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan","family":"Ishtiaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umar","family":"Zahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,11,16]]},"reference":[{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s10741-015-9502-y","article-title":"Chemotherapy-induced cardiomyopathy","volume":"20","author":"Higgins","year":"2015","journal-title":"Heart Fail Rev"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.827"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.3","doi-asserted-by":"publisher","DOI":"10.1023\/A:1007094214460"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.4","doi-asserted-by":"publisher","DOI":"10.1124\/mol.63.4.849"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.5","first-page":"8","article-title":"Chemotherapy induced cardiomyopathy: pathogenesis, monitoring and management","volume":"13","author":"Shakir","year":"2009","journal-title":"J Clin Med Res"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.6","doi-asserted-by":"publisher","DOI":"10.2174\/187152508785909474"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2006.10.002"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"01","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.9","doi-asserted-by":"publisher","DOI":"10.1053\/S0093-7754(06)00041-8"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.10","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3109\/08880018.2011.563772","article-title":"The value of echocardiography versus cardiactroponin I levels in the early detection of anthracyclinecardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up","volume":"28","author":"Oztarhan","year":"2011","journal-title":"Pediatr Hematol Oncol"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3109\/08880018.2013.851753","article-title":"Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?","volume":"31","author":"Basar","year":"2014","journal-title":"Pediatr Hematol Oncol"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.12","doi-asserted-by":"publisher","DOI":"10.1179\/102453312X13376952196412"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.13","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.439"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.14","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.5114\/aoms.2013.34987","article-title":"Prognostic role of troponin and natriuretic peptides as biomarkers for deterioration of left ventricular ejection fraction after chemotherapy","volume":"10","author":"Stachowiak","year":"2014","journal-title":"Arch Med Sci"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.15","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-013-1267-1"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.16","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-011-0291-4"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.17","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.clinbiochem.2013.06.029","article-title":"Growth-differentiation factor-15 and tissue Doppler \u0131maging in detection of asymptomatic anthracycline cardiomyopathy in childhood cancer survivors","volume":"46","author":"Arslan","year":"2013","journal-title":"Clin Biochem"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.18","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.173179"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.19","first-page":"A11619","article-title":"Topoisomerase 2\u00df expression in peripheral blood predicts susceptibility to anthracycline-induced cardiomyopathy","volume":"128","author":"Vejpongsa","year":"2013","journal-title":"Circulation"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf231"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.21","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/clpt.2013.201","article-title":"Topoisomerase 2\u03b2: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity","volume":"95","author":"Vejpongsa","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.22","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2004.08.006"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.23","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000054201.60308.1A"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.24","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-10-337"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197902083000603"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.26","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19850615)55:12<2761::AID-CNCR2820551206>3.0.CO;2-P"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11407"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.28","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-125-1-199607010-00008"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.29","first-page":"135","article-title":"Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy","volume":"35","author":"Wang","year":"2013","journal-title":"ZhonghuaZhong Liu ZaZhi"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.30","doi-asserted-by":"crossref","first-page":"651630","DOI":"10.1155\/2012\/651630","article-title":"Selenium in the prevention of anthracycline-induced cardiac toxicity in children with cancer","volume":"2012","author":"Tacyildiz","year":"2012","journal-title":"J Oncol"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2011.01.018"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.32","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phrs.2013.11.001","article-title":"Ranolazine in the prevention of anthracycline cardiotoxicity","volume":"79","author":"Corradi","year":"2014","journal-title":"Pharmacol Res"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.33","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.65"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.34","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2013.0150"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.03.095"},{"key":"2025042705462886000_2016.nov16_1.bcr2016217210.36","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf132"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2016-217210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,27]],"date-time":"2025-04-27T12:46:39Z","timestamp":1745757999000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2016-217210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,16]]},"references-count":36,"alternative-id":["10.1136\/bcr-2016-217210"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2016-217210","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,16]]}}}